- |||||||||| letrozole / Generic mfg., clomifene citrate / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: COOL-COS: COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (clinicaltrials.gov) - Dec 4, 2015 P4, N=28, Completed, Active, not recruiting --> Recruiting Enrolling by invitation --> Completed | N=40 --> 28 | Trial primary completion date: Oct 2015 --> Mar 2015
- |||||||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Phase classification, Enrollment change, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Nov 16, 2015 P1, N=200, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Aug 2019 Phase classification: P1/2 --> P1 | N=300 --> 200
- |||||||||| letrozole / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Study of Breast Cancer Prevention by Letrozole in High Risk Women (clinicaltrials.gov) - Nov 10, 2015 P2, N=55, Completed, Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | N=108 --> 55 | Trial primary completion date: Jul 2015 --> Mar 2015
- |||||||||| letrozole / Generic mfg.
Enrollment closed, Trial primary completion date: Aromatase Inhibitor Host Factors Study (clinicaltrials.gov) - Oct 20, 2015 P=N/A, N=140, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jun 2015
- |||||||||| letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Oct 14, 2015 P2, N=20, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jun 2015 Recruiting --> Active, not recruiting
- |||||||||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Sep 2, 2015 P3, N=270, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Mar 2021 --> Sep 2021
|